Publications by authors named "Giulio Maresca"
Edoxaban for the treatment of pulmonary embolism in hospitalized COVID-19 patients.
Expert Rev Clin Pharmacol
October 2021
Purpose: We aimed to investigate the clinical performance of edoxaban for the treatment of pulmonary embolism (PE) in hospitalized COVID-19 patients.
Methods: We conducted a retrospective analysis selecting hospitalized patients with COVID-19 admitted to our Institution from 20 May 2020 to 20 November 2020 with computer tomography (CT) detected PE at admission, treated with edoxaban after initial parenteral therapy. Clinical outcomes were compared between patients with and without ARDS at admission and between those with and without CT confirmed PE resolution.
Article Synopsis
- The study analyzed the effectiveness of hydroxychloroquine (HCQ) in treating COVID-19 by observing 4,396 patients hospitalized in Italy from February to May 2020, revealing mixed results from previous research.
- Two patient clusters were identified: a younger, healthier group at lower risk of death and an older, sicker group at higher risk, highlighting differing impacts of HCQ on these populations.
- HCQ appeared to significantly reduce mortality risk in the lower risk cluster, suggesting that it may be more beneficial for patients with fewer comorbidities, potentially clarifying debates around its efficacy in COVID-19 treatment.
Protease inhibitors have been considered as possible therapeutic agents for COVID-19 patients. To describe the association between lopinavir/ritonavir (LPV/r) or darunavir/cobicistat (DRV/c) use and in-hospital mortality in COVID-19 patients. Multicenter observational study of COVID-19 patients admitted in 33 Italian hospitals.
View Article and Find Full Text PDFArticle Synopsis
- - The study investigated whether administering heparin in hospitals improves survival rates among COVID-19 patients, due to a linked hypercoagulable condition that can worsen the disease.
- - An analysis of 2,574 patients across Italy showed that 70.1% received heparin, leading to significantly lower death rates (7.4 vs. 14.0 per 1,000 person-days) among those treated with heparin.
- - The findings suggest that heparin is associated with a 40% reduction in death risk, especially for critically ill patients, indicating its potential benefit, although further randomized clinical trials are necessary for definitive guidance.
Common cardiovascular risk factors and in-hospital mortality in 3,894 patients with COVID-19: survival analysis and machine learning-based findings from the multicentre Italian CORIST Study.
Nutr Metab Cardiovasc Dis
October 2020
Article Synopsis
- A study investigated factors contributing to in-hospital death among COVID-19 patients in Italy, analyzing data from 3,894 hospitalized individuals from February to May 2020.
- Key findings showed that impaired renal function, high levels of C-reactive protein, and older age were significant predictors of mortality, with the highest death rates found in Northern Italy (15.6%) compared to Central/Southern regions (6.4%).
- The results indicated that factors like obesity, tobacco use, and cardiovascular conditions did not correlate with mortality risk, emphasizing the importance of renal health and inflammation in COVID-19 outcomes.